Is There Already a Need of Reckoning on Cancer Immunotherapy?

Front Pharmacol. 2021 Mar 26:12:638279. doi: 10.3389/fphar.2021.638279. eCollection 2021.

¹ Unit of Medical Oncology, Oncology Department, Grand Metropolitan Hospital 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
² Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.
³ Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, PA, United States.
⁴ Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Salford, United Kingdom.
⁵ Tissue Typing Unit, Grand Metropolitan Hospital 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
⁶ Department of Medical Biotechnologies, University of Siena, Siena, Italy.
⁷ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United States.

No abstract available

Keywords: cancer; immunotherapy; mesothelioma; real world evidences; study design.